

**Supplemental Table S8.** Annual Economic Benefit per Patient from RDA DPP4 Inhibitor Prescription for Impaired Kidney Function (2012 to 2018)

Variable	Medical expenditure (2012–2018)			Cost reduction	
	Cost in CKD, \$	Model 1, \$	Model 2, \$	Model 1, %	Model 2, %
CKD-EPI eGFR <60 mL/min/1.73 m <sup>2</sup>					
Total	222.7	-17.0	-34.2	-7.6	-15.4
Outpatient	222.4	-16.6	-33.3	-7.5	-15.0
Inpatient	229.7	-23.2	-57.4	-10.2	-25.1
CKD-EPI eGFR <45 mL/min/1.73 m <sup>2</sup>					
Total	209.8	-47.2	-82.3	-22.5	-39.3
Outpatient	208.9	-47.0	-81.3	-22.5	-39.0
Inpatient	226.2	-44.9	-102.1	-20.1	-45.4
CKD-EPI eGFR <30 mL/min/1.73 m <sup>2</sup>					
Total	212.9	-64.3	-108.2	-30.4	-51.2
Outpatient	211.2	-64.5	-107.7	-30.7	-51.3
Inpatient	230.9	-55.2	-120.7	-24.3	-52.9

RDA, renal dose-adjusted; DPP4, dipeptidyl peptidase-4; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.